Neil MacLean
Overview
Explore the profile of Neil MacLean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tin E, Rutella S, Khatri I, Na Y, Yan Y, MacLean N, et al.
Blood Cancer Discov
. 2025 Feb;
PMID: 39928733
Despite the curative potential of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML), its efficacy is limited by intrinsic resistance of cancer cells to donor-derived T-cell cytotoxicity. Using...
2.
Thomas G, Egan G, Garcia-Prat L, Botham A, Voisin V, Patel P, et al.
Nat Cell Biol
. 2022 Jun;
24(6):872-884.
PMID: 35668135
Mitochondrial metabolites regulate leukaemic and normal stem cells by affecting epigenetic marks. How mitochondrial enzymes localize to the nucleus to control stem cell function is less understood. We discovered that...
3.
Nachmias B, Khan D, Voisin V, Mer A, Thomas G, Segev N, et al.
Leukemia
. 2022 Feb;
36(5):1283-1295.
PMID: 35152270
AML cells are arranged in a hierarchy with stem/progenitor cells giving rise to more differentiated bulk cells. Despite the importance of stem/progenitors in the pathogenesis of AML, the determinants of...
4.
Lee J, Khan D, Hurren R, Xu M, Na Y, Kang H, et al.
Blood
. 2021 Jul;
138(3):234-245.
PMID: 34292323
Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy....
5.
Barghout S, Aman A, Nouri K, Blatman Z, Arevalo K, Thomas G, et al.
JCI Insight
. 2021 Jan;
6(5).
PMID: 33476303
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243...
6.
Schimmer A, Singh R, Seneviratne A, Thomas G, MacLean N, Hurren R
STAR Protoc
. 2020 Dec;
1(3):100163.
PMID: 33377057
We describe a method to silence genes in primary acute myeloid leukemia cells by transducing them with shRNA in lentiviral vectors. The transduction of primary non-adherent cells is particularly challenging....
7.
Singh R, Jeyaraju D, Voisin V, Hurren R, Xu C, Hawley J, et al.
Cell Stem Cell
. 2020 May;
26(6):926-937.e10.
PMID: 32416059
Leukemic stem cells (LSCs) rely on oxidative metabolism and are differentially sensitive to targeting mitochondrial pathways, which spares normal hematopoietic cells. A subset of mitochondrial proteins is folded in the...
8.
Khan D, Mullokandov M, Wu Y, Voisin V, Gronda M, Hurren R, et al.
Blood
. 2020 Apr;
136(1):81-92.
PMID: 32299104
Through a clustered regularly insterspaced short palindromic repeats (CRISPR) screen to identify mitochondrial genes necessary for the growth of acute myeloid leukemia (AML) cells, we identified the mitochondrial outer membrane...
9.
Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, et al.
Sci Transl Med
. 2020 Apr;
12(538).
PMID: 32269163
Neurolysin (NLN) is a zinc metallopeptidase whose mitochondrial function is unclear. We found that NLN was overexpressed in almost half of patients with acute myeloid leukemia (AML), and inhibition of...
10.
Bankar A, Siriwardena T, Rizoska B, Rydergard C, Kylefjord H, Rraklli V, et al.
Haematologica
. 2019 Dec;
106(2):574-579.
PMID: 31857370
No abstract available.